Durable Prevention of Recurrent C. Difficile Infection with RBX2660: Results of the PUNCH CD 2 Trial

Ramesh, Mayur; Khanna, Sahil; Messer, Julie; Adams, Matt

doi:10.14309/00000434-201610001-00194

Cited by 2 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seres health also developed SER-287 for the treatment of IBD and in specific ulcerative colitis (Inflammatory Bowel Disease | Seres Therapeutics, 2017 ). Rebiotix commercially developed RBX2660, a mix of live human microbes for effective treatment of recurrent CDI ( Ramesh et al, 2016 ). Moreover, other formulations including strains belonging to Clostridia classes IV and XIVa were designed to modulate the immune response ( Atarashi et al, 2013 ).…”

Section: Industrial Applications and Interestsmentioning

confidence: 99%

Emerging Trends in “Smart Probiotics”: Functional Consideration for the Development of Novel Health and Industrial Applications

2017

View full text Add to dashboard Cite

The link between gut microbiota and human health is well-recognized and described. This ultimate impact on the host has contributed to explain the mutual dependence between humans and their gut bacteria. Gut microbiota can be manipulated through passive or active strategies. The former includes diet, lifestyle, and environment, while the latter comprise antibiotics, pre- and probiotics. Historically, conventional probiotic strategies included a phylogenetically limited diversity of bacteria and some yeast strains. However, biotherapeutic strategies evolved in the last years with the advent of fecal microbiota transplant (FMT), successfully applied for treating CDI, IBD, and other diseases. Despite the positive outcomes, long-term effects resulting from the uncharacterized nature of FMT are not sufficiently studied. Thus, developing strategies to simulate the FMT, using characterized gut colonizers with identified phylogenetic diversity, may be a promising alternative. As the definition of probiotics states that the microorganism should have beneficial effects on the host, several bacterial species with proven efficacy have been considered next generation probiotics. Non-conventional candidate strains include Akkermansia muciniphila, Faecalibacterium prausnitzii, Bacteroides fragilis, and members of the Clostridia clusters IV, XIVa, and XVIII. However, viable intestinal delivery is one of the current challenges, due to their stringent survival conditions. In this review, we will cover current perspectives on the development and assessment of next generation probiotics and the approaches that industry and stakeholders must consider for a successful outcome.

show abstract

Section: Industrial Applications and Interestsmentioning

confidence: 99%